GlaxoSmithKline reports positive data from Shingrix vaccine trial

GlaxoSmithKline has announced new clinical trial data that demonstrates the safety and efficacy of its shingles vaccine Shingrix.

Data from the phase III ZOE-HSCT study supports the safety and efficacy of Shingrix in preventing shingles among adults aged 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant.

In subjects aged 50 and above, the rate of efficacy was similar, with the vaccine reducing overall complications linked to shingles episodes by 77.76 percent. Additionally, 89.27 percent of patients were able to avoid postherpetic neuralgia, a form of chronic nerve pain and the most common complication associated with shingles.

Emmanuel Hanon, senior vice-president and head of vaccines for GlaxoSmithKline, said: "Today's results, demonstrating the vaccine's ability to help prevent shingles and its complications with just two doses, may provide a much-needed benefit to these patients considering the high incidence and burden of disease they face."

Shingrix is a non-live, recombinant adjuvanted subunit vaccine given intramuscularly in two doses. It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant to generate a strong and sustained immune response.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.